It has been concluded that the use of factor VII in children has rapidly increased in the last few years, the mortality among patients receiving factor VII for off-label indications is higher and there is a higher incidence of thrombotic events.
Se concluye que el uso de factorvii en niños ha aumentado rápidamente durante los últimos anos, la mortalidad de los pacientes que reciben factorvii con indicaciones off label es más alta y existe mayor incidencia de eventos trombóticos.